The psoriasis drug market is about to become a lot more competitive. An array of drug companies are working at a fast clip to bring novel prescription drugs to market to treat patients with moderate to severe forms of the disease. The commercial success of biologics like Amgen Inc.’s Enbrel (etanercept) and Abbott Laboratories Inc.’s Humira (adalimumab) have shown that a significant market opportunity exists for systemic drugs that can clear up the painful inflamed skin lesions caused by psoriasis.
The three tumor necrosis factor inhibitors already approved for psoriasis have set a high bar for new systemic drugs coming...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?